What's in M. Peter Marinkovich's pipeline?

M. Peter Marinkovich has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with M. Peter Marinkovich's portfolio?

Top competitors by shared drug class: Adrienne G. Waks, Argenx Bv, Genentech, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/m-peter-marinkovich.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

M. Peter Marinkovich — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

M. Peter Marinkovich pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Efgartigimod	Efgartigimod	marketed	Endoglycosidase [EPC]	FcRn	Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Adrienne G. Waks · 1 shared drug class
Argenx Bv · 1 shared drug class
Genentech, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for M. Peter Marinkovich:

Cite this brief

Drug Landscape (2026). M. Peter Marinkovich — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/m-peter-marinkovich. Accessed 2026-06-10.